Moreover, targeted therapies directed against the PI3K/AKT/mTOR pathway, either alone or in combination with chemotherapeutic agents, have significantly contributed to overcoming treatment resistance in AML [19,20,21,22,23]. The gene discussed is AKT1; the disease is acute myeloid leukemia.